Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy

Expert Opin Pharmacother. 2002 Dec;3(12):1739-51. doi: 10.1517/14656566.3.12.1739.


Doxorubicin, either as a single agent or in combination regimens, is considered to be one of the most active chemotherapeutic agents in the treatment of metastatic breast cancer. However, its clinical utility is limited by a cumulative, dose-dependent cardiac myopathy that can lead to potentially fatal congestive heart failure. Considerable research has gone into improving the therapeutic index of doxorubicin-based regimens. A new liposomal formulation of doxorubicin (Myocet, Elan Pharmaceuticals) has a significantly improved therapeutic index compared with conventional doxorubicin. The development of Myocet, a less cardiotoxic, better tolerated and equally efficacious doxorubicin, extends the therapeutic options in the overall management of breast cancer.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Clinical Trials as Topic
  • Doxorubicin / adverse effects
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use*
  • Female
  • Humans
  • Liposomes


  • Antineoplastic Agents
  • Liposomes
  • Doxorubicin